Amgen 2002 Annual Report Download - page 22

Download and view the complete annual report

Please find page 22 of the 2002 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 72

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72

Page 20
Selected Amgen Products and Product Candidates
Selected Products and Development Phase
Therapeutic Areas Product Candidates Phase 1 Phase 2 Phase 3 Filed Approved
Nephrology
Anemia EPOGEN
®
(Epoetin alfa) ●●●●●
Anemia Aranesp
®
(darbepoetin alfa) ●●●●●
Secondary hyperparathyroidism Cinacalcet hydrochloride ●●●
Hematology & Oncology
Neutropenia NEUPOGEN
®
(Filgrastim) ●●●●●
PBPC mobilization NEUPOGEN
®
●●●●●
Neutropenia Neulasta
™
(pegfilgrastim) ●●●●●
Anemia Aranesp
®
●●●●●
Non-Hodgkin’s lymphoma Epratuzumab ●●●
Mucositis KGF
(1)
●●●
EGF receptor ABX-EGF ●●
Metastatic bone disease Osteoprotegerin program ●
Bone & Inflammation
Rheumatoid arthritis ENBREL
®
(etanercept) ●●●●●
Polyarticular-course juvenile
rheumatoid arthritis ENBREL
®
●●●●●
Psoriatic arthritis ENBREL
®
●●●●●
Rheumatoid arthritis Kineret
®
(anakinra) ●●●●●
Ankylosing spondylitis ENBREL
®
●●●●
Psoriasis ENBREL
®
●●●
Rheumatoid arthritis PEG-sTNF-R1
(2)
●●
Osteoporosis Osteoprotegerin program ●●
Neurology & Endocrinology
Primary hyperparathyroidism Cinacalcet hydrochloride ●●
Parkinson’s disease GDNF
(3)
●●
Phase 1 Clinical Trial
Investigate safety and proper dose ranges of a product candidate in a small number of human subjects.
Phase 2 Clinical Trial
Investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.
Phase 3 Clinical Trial
Investigate safety and efficacy of product candidate in a large number of patients who have the disease or condition under study.
(1)
Keratinocyte growth factor
(2)
PEGylated soluble tumor necrosis factor-type 1 receptor
(3)
Glial cell-line derived neurotrophic factor